Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Acura Pharmaceuticals Inc (ACUR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012266
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acura Pharmaceuticals Inc (Acura) is a specialty pharmaceutical company that researches, develops, and commercializes tamper-resistant products to prevent the abuse and misuse of medication. The company’s proprietary technologies, Aversion, Limitx and Impede, are used to prevent product tampering associated with opioid abuse. Its Impede technology helps minimize the extraction and conversion of pseudoephedrine into methamphetamine. Limitx reduces the level of opioid release when several tablets are swallowed. Aversion irritates the nasal passages upon snorting the product Its product portfolio includes Oxaydo, an opioid analgesic; Nexafed and Nexafed Sinus Pressure plus that contain pseudoephedrine. The company markets its products in the US and Canada. Acura is headquartered in Palatine, Illinois, the US.

Acura Pharmaceuticals Inc (ACUR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acura Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Licensing Agreements 13
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 13
KemPharm Enters into Licensing Agreement with Acura Pharma 15
Egalet Enters into Licensing Agreement with Acura Pharma 16
Equity Offering 17
Acura Pharma Raises USD4 Million in Private Placement of Units 17
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 18
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 19
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 21
Acquisition 22
Acura Pharma Plans to Sell Itself 22
Acura Pharmaceuticals Inc – Key Competitors 23
Acura Pharmaceuticals Inc – Key Employees 24
Acura Pharmaceuticals Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 13, 2017: Acura Pharmaceuticals Announces Third Quarter 2017 Financial Results 26
Aug 14, 2017: Acura Pharmaceuticals Announces Second Quarter 2017 Financial Results 27
May 12, 2017: Acura Pharmaceuticals Announces First Quarter 2017 Financial Results 28
Mar 31, 2017: Acura Pharmaceuticals Announces Fourth Quarter 2016 and Full Year 2016 Financial Results 29
Nov 14, 2016: Acura Pharmaceuticals Announces Third Quarter 2016 Financial Results 30
Aug 08, 2016: Acura Pharmaceuticals Announces Second Quarter 2016 Financial Results 31
May 02, 2016: Acura Pharmaceuticals Announces First Quarter 2016 Financial Results 32
Feb 29, 2016: Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results 33
Product News 34
09/11/2017: Acura Pharmaceuticals Presenting New LIMITx Clinical Data at the 19th Annual Rodman & Renshaw Conference 34
07/11/2016: Acura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400 35
06/28/2017: Acura Pharmaceuticals Advances LTX-04 and its LIMITx Technology 36
04/13/2016: Acura Pharmaceutical Limitx Technology Successfully Demonstrates Oral Abuse Deterrence 37
Product Approvals 39
Dec 14, 2016: Acura Pharmaceutical Provides Development Update on its LIMITx Technology 39
Apr 12, 2016: Acura Pharmaceuticals Announces FDA Fast Track Designation for the Development of LTX-04 40
Clinical Trials 41
May 18, 2017: Acura Pharmaceutical Initiates Second Clinical Study on LTX-04 41
Jun 08, 2016: Acura Pharmaceuticals LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities 42
Feb 01, 2016: Acura Pharmaceuticals Provides Development Update on Its oral abuse deterrent drug LIMITX 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acura Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acura Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 11
Acura Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
MainPointe Pharma Enters into Licensing Agreement with Acura Pharma 13
KemPharm Enters into Licensing Agreement with Acura Pharma 15
Egalet Enters into Licensing Agreement with Acura Pharma 16
Acura Pharma Raises USD4 Million in Private Placement of Units 17
Acura Pharmaceuticals Files Registration Statement for Public Offering of Shares 18
Acura Pharma Raises USD7.6 Million in Private Placement of Shares 19
Acura Pharma Completes Second Tranche Of Public Offering Of Shares For US$3.4 Million 21
Acura Pharma Plans to Sell Itself 22
Acura Pharmaceuticals Inc, Key Competitors 23
Acura Pharmaceuticals Inc, Key Employees 24
Acura Pharmaceuticals Inc, Other Locations 25
Acura Pharmaceuticals Inc, Subsidiaries 25

★海外企業調査レポート[Acura Pharmaceuticals Inc (ACUR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MyCartis NV-医療機器分野:企業M&A・提携分析
    Summary MyCartis NV (MyCartis), formerly Pronota NV is a biomarker analysis solution provider. The company develops multiplexed biomarker solutions through evalution and bio assays technology. It uses technologies such as barcoded microparticles, microfluidic assay cartridges and evalution instrumen …
  • Qantas Airways Limited:企業の戦略・SWOT・財務情報
    Qantas Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Qantas Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • OGD2 Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary OGD2 Pharma SAS (OGD2 Pharma) is an independent pre-clinical stage biotechnology company that researches, develops and commercializes cancer immunotherapies targeting the O-acetylated form of the GD2 ganglioside (OAcGD2). The company pipeline product portfolio includes OGD201, a humanized mo …
  • MSL Solutions Limited (MPW):企業の財務・戦略的SWOT分析
    MSL Solutions Limited (MPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Beltrami Electric Cooperative, Inc.:発電所・企業SWOT分析
    Beltrami Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • BEKB | BCBE Private Banking:企業の戦略・SWOT・財務情報
    BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report Summary BEKB | BCBE Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Entertainment One Ltd.:企業の戦略・SWOT・財務分析
    Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report Summary Entertainment One Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Zain Group (ZAIN):企業の財務・戦略的SWOT分析
    Zain Group (ZAIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CeoTronics AG (CEK):企業の財務・戦略的SWOT分析
    CeoTronics AG (CEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • QRxPharma Ltd:企業の戦略的SWOT分析
    QRxPharma Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • WorleyParsons Ltd (WOR):企業の財務・戦略的SWOT分析
    WorleyParsons Ltd (WOR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Pacific Energy Ltd (PEA):企業の財務・戦略的SWOT分析
    Summary Pacific Energy Ltd (PEL) operates as a power generation company that develops, operates and maintains renewable energy power stations. The company operates Kalgoorlie Power Systems that operates site locations across Northern Territory, Western Australia and South Australia, among others. It …
  • Harley-Davidson, Inc.:企業の戦略・SWOT・財務情報
    Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report Summary Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lycera Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Lycera Corp (Lycera) is a biopharmaceutical company that focuses on the development of oral immune modulators for the treatment of patients with autoimmune diseases and cancer. The company’s pipeline products include LYC-55716, an oral retinoic acid-related orphan receptor gamma (RORgamma) a …
  • Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …
  • Alphabet Inc:企業の戦略・SWOT・財務情報
    Alphabet Inc - Strategy, SWOT and Corporate Finance Report Summary Alphabet Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Sirius XM Holdings Inc.:企業の戦略・SWOT・財務情報
    Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Sirius XM Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Ushdev International Limited (511736):企業の財務・戦略的SWOT分析
    Ushdev International Limited (511736) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • KCC Corp (002380):企業の財務・戦略的SWOT分析
    KCC Corp (002380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cytune Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Cytune Pharma SAS (Cytune) is a health care product developer that develops immunotherapeutic agents for the treatment of cancer and infectious diseases. The company’s product portfolio includes recombinant proteins and monoclonal antibodies. Its CYP0150 is a recombinant protein, which decre …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆